Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk ...

Analysts have set 12-month price targets for Septerna, revealing an average target of $20.0, a high estimate of $26.00, and a low estimate of $11.00. Witnessing a positive shift, the current average ...

Fintel reports that on June 23, 2025, HC Wainwright & Co. initiated coverage of Septerna (NasdaqGM:SEPN) with a Buy ...

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform.

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership: 16.05. Cantor Fitzgerald lifts Septerna stock to $25 target, maintains overweight: 16.05. Septerna, Inc. GAAP EPS of -$0 ...

Septerna ended the quarter with $398.2 million in cash, cash equivalents, and marketable securities. The recent Novo Nordisk partnership is expected to significantly extend its cash runway beyond ...

Septerna also has an option to profit-share on one of the programmes. Image. Phil Taylor. 14 May, 2025. obesity. Bookmark this. R&D Built for one: The case for custom formulation in the era of ...

Septerna Inc. is listed on the CBOE trading with ticker code SEPN.US. It has a market capitalisation of $466.53m, with approximately 44.56m shares in issue. Over the last year, Septerna Inc. share ...

TD Cowen reiterated its Buy rating and $105.00 price target on Novo Nordisk (NYSE: NVO) Wednesday following meetings with the company’s senior leadership in Copenhagen. The pharmaceutical giant, with ...

Recently, Novo Nordisk signed a $2.2 billion deal with Septerna for developing and commercializing oral small-molecule medicines for treating obesity, type II diabetes (T2D) and other ...